Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) EBT (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed EBT for 7 consecutive years, with -$194.8 million as the latest value for Q4 2025.

  • Quarterly EBT rose 26.85% to -$194.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$704.0 million through Dec 2025, down 34.08% year-over-year, with the annual reading at -$732.5 million for FY2025, 35.1% down from the prior year.
  • EBT hit -$194.8 million in Q4 2025 for BridgeBio Pharma, down from -$186.5 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$19.1 million in Q1 2024 to a low of -$266.2 million in Q4 2024.
  • Historically, EBT has averaged -$155.4 million across 5 years, with a median of -$163.2 million in 2023.
  • Biggest five-year swings in EBT: surged 86.59% in 2024 and later tumbled 640.71% in 2025.
  • Year by year, EBT stood at -$180.6 million in 2021, then grew by 19.62% to -$145.1 million in 2022, then tumbled by 32.37% to -$192.1 million in 2023, then crashed by 38.59% to -$266.2 million in 2024, then increased by 26.85% to -$194.8 million in 2025.
  • Business Quant data shows EBT for BBIO at -$194.8 million in Q4 2025, -$186.5 million in Q3 2025, and -$181.7 million in Q2 2025.